covid-19 vaccine Merck

European regulators to speed review of COVID-19 antiviral drug

Reading now: 978
www.cidrap.umn.edu

The European Medicines Agency said today that it has started a rolling review of molnupiravir, an oral antiviral drug developed by Merck and Ridgeback Biotherapeutics for treating newly diagnosed COVID-19 in adults.In a statement, the EMA said its decision to start the assessment is based on preliminary findings that suggest the drug may reduce SARS-CoV-2 replication, which could play a role in preventing hospitalization and death.The agency notes that a rolling review—a tool used to speed assessment during public health emergencies—will continue until the companies have enough evidence to submit a formal authorization application.The development follow's Merck's Oct 11 announcement that it and Ridgeback had submitted an emergency use

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA